Education and Communication on the Topic of Osteonecrosis of the Jaw When Taking Bone‐Stabilizing Drugs
Clinical and Experimental Dental Research · 2024
DOI: 10.1002/cre2.70024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dental Research, 2024. Verfasst von Franz Gustav Saur und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medizinische Klinik II, Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany. Hauptthemen laut MEDLINE: Patient Education as Topic, Bisphosphonate-Associated Osteonecrosis of the Jaw, Communication, Quality of Life. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Objectives
The aim of this study was to analyze the communication between doctors and patients who were taking bone‐stabilizing medication and in rare cases developed osteonecrosis of the jaw as a result. Material and Methods A standardized questionnaire recorded deficits based on patient experiences. These data were used to develop solution strategies for improving doctor–patient communication and the benefit–risk assessment of medication use.
Results
Most patients were satisfied with the information provided by their doctor; however, one in three (29.8%) were not informed about possible side effects, and a quarter (24.6%) only found out about osteonecrosis of the jaw through their own research. Only half (45.7%) were asked about risk factors, and most information materials were rated poorly. The diagnosis took an average of 18.7 months, with many (47.8%) consulting a doctor only when they experienced pain. Quality of life was severely impaired, with daily pain, physical limitations, and negative effects on mental health. About a third (35.3%) reported that their quality of life had deteriorated significantly.
Conclusions
Further research into patient education is necessary. Web‐based information brochures, improved follow‐up care, and close cooperation with dentists are required. The use of a running sheet, such as the AGSMO running sheet, for individual risk assessment of osteonecrosis of the jaw is recommended. Patients undergoing treatment with bone‐stabilizing medication should be monitored closely. Education about osteonecrosis of the jaw must be continued, and the medical profession must be confronted with it.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medizinische Klinik II, Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.
- Deutsche Krebsgesellschaft, Berlin, Germany.
- Südharz klinikum, Klinik für HNO-Erkrankungen, Kopf-Hals-Chirurgie und Interdisziplinäre Palliativstation, Nordhausen, Germany.
ORCID-Profile: Franz Gustav Saur, Christian Keinki
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Saur, F. G., Keinki, C., Cramer, A., Buentzel, J., & Hübner, J. (2024). Education and Communication on the Topic of Osteonecrosis of the Jaw When Taking Bone‐Stabilizing Drugs. Clinical and Experimental Dental Research. https://doi.org/10.1002/cre2.70024
Vancouver
Saur FG, Keinki C, Cramer A, Buentzel J, Hübner J. Education and Communication on the Topic of Osteonecrosis of the Jaw When Taking Bone‐Stabilizing Drugs. Clinical and Experimental Dental Research. 2024. doi:10.1002/cre2.70024
BibTeX
@article{Saur2024,
author = {Saur, Franz Gustav and Keinki, Christian and Cramer, Alin and Buentzel, Jens and Hübner, Jutta},
title = {Education and Communication on the Topic of Osteonecrosis of the Jaw When Taking Bone‐Stabilizing Drugs},
journal = {Clinical and Experimental Dental Research},
year = {2024},
doi = {10.1002/cre2.70024}
}
EUVIMED